Late-Stage Bispecifics and ADCs in DLBCL
Sarah Rutherford, MD
John P. Leonard, MD
Patient Selection for ADCs in First-Line DLBCL
Bispecific Antibodies in FL
Kami Maddocks, MD
Matthew J. Matasar, MD
Application of Data from the ECHELON-1 Trial
Alison J. Moskowitz, MD
Alex Herrera, MD
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
NCCN Guideline Updates in DLBCL
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Antibody-Drug Conjugates in FL
Individualizing Frontline Treatment
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
Paul P. Doghramji, MD, FAAFP
Rami Komrokji, MD
Allan Platt, PA-C, MMSc
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
Jason J. Luke, MD, FACP
Elizabeth Buchbinder, MD
Metastatic Melanoma: Solving Clinical Dilemmas in Frontline ICI Treatment
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Vivek Subbiah, MD
Impact of Infertility & Elective Fertility Among Female Oncologists
Emily MacDuffie, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.